基于结构的设计小分子抑制剂的人类介质素-6的结构
Ankit Joshi1, Zhousheng Xiao2, Shreya Suman1
1Computational Biophysics Lab, Indian Institute of Technology (Indian School of Mines) Dhanbad, Dhanbad 826004, Jharkhand, India.
Molecules (Basel, Switzerland)
|July 30, 2025
概括
研究人员选了人类中白素-6 (hIL-6) 的小分子抑制剂,这是一个关键的炎症媒介. 一种化合物显著抑制了hIL-6信号传递,为新的治疗策略提供了潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 计算化学的计算化学
背景情况:
- 人类介质素-6 (hIL-6) 是一种促炎性细胞因子,是各种疾病的核心.
- 目前的治疗包括针对hIL-6或其受体 (IL-6Rα) 的单克隆抗体.
- 需要替代治疗方式,如小分子抑制剂.
研究的目的:
- 通过计算查来识别hIL-6的新型小分子抗剂.
- 通过体外测试来评估已识别的化合物的治疗潜力.
主要方法:
- 使用集体对接的基于高通量结构的计算选.
- 模拟apoprotein的分子动力学模拟,以产生目标形状.
- 从实验研究中对接触点的先验知识的纳入.
- 在体外功能测试以验证计算识别的连接体.
主要成果:
- 计算选确定了得分最高的小分子配体.
- 一种具有第二高结合亲和度的化合物在10μM时表现出~84%的IL6诱导的STAT3记者活性抑制.
- 这表明计算机设计的抑制剂在体外有效性显著.
结论:
- 该研究成功地确定了一种强大的小分子抑制剂hIL-6.
- 这些发现支持开发针对hIL-6的小分子药物,用于治疗应用.
- 这种方法可能会加速对hIL-6介导疾病的新治疗方法的发现.
相关概念视频
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Protein-protein Interfaces
13.3K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.3K


